Akero Therapeutics Inc., a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced the publication of results from the Phase 2b HARMONY clinical trial in The Lancet. The study evaluated the efficacy of efruxifermin $(EFX)$ in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) over a 96-week period. The results indicate that 49% of participants receiving 50mg EFX showed at least one stage improvement in liver fibrosis without worsening MASH, compared to 19% for the placebo group (p=0.0030). These findings were supported by digital pathology and improvements in non-invasive markers such as liver stiffness and ELF score. The trial was a multicenter, randomized, double-blind, placebo-controlled study, which confirmed the potential of EFX to address liver fibrosis and metabolic health in affected individuals.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.